Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Acinetobacter baumannii Infections
Preprint
- 5 November 2024
- preprint
- Published by MDPI AG in Preprints.org
Abstract
The emergence of antibiotic-resistant Acinetobacter baumannii (A. baumannii) is a pressing threat in clinical settings. As the last line of defense, colistin is currently widely used to treat multidrug-resistant A. baumannii. Unfortunately colistin-resistant phenotypes in A.baumannii isolates have also been reported, highlighting the desperate need to develop alternative medications to address these serious bugs. To resist colistin, A. baumannii has developed several mechanisms. These include the loss of outer membrane lipopolysaccharide (LPS) due to mutation of LPS biosynthetic genes, modification of lipid A (a constituent of LPS) structure through the addition of phosphoethanolamine (PEtN) moieties to the lipid A component by overexpression of chromosomal pmrCAB operon genes and eptA gene, or acquisition plasmid-encoded mcr genes through horizontal gene transfer. Other resistance mechanisms involve alterations of outer membrane permeability through porins, expulsion of colistin by efflux pumps and heteroresistance. In response to the rising threat of colistin-resistant A. baumannii, researchers have developed various treatment strategies, including antibiotic combination therapy, adjuvants to potentiate antibiotic activity, repurposing existing drugs, antimicrobial peptides, nanotechnology, photodynamic therapy, CRISPR/Cas and phage therapy. While many of these strategies have shown promise in vitro and in vivo, further clinical trials are necessary to ensure their efficacy and widen their clinical applications. Ongoing research is crucial to identify optimal therapeutic strategies for managing colistin-resistant A. baumannii. This review explores the genetic mechanisms underlying colistin resistance and assesses potential treatment options for this challenging pathogen.Keywords
All Related Versions
This publication has 165 references indexed in Scilit:
- Artificial intelligence for drug repurposing against infectious diseasesArtificial Intelligence Chemistry, 2024
- Rescuing humanity by antimicrobial peptides against colistin-resistant bacteriaApplied Microbiology and Biotechnology, 2022
- Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?Current Microbiology, 2021
- In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumanniiApplied Biochemistry and Biotechnology, 2021
- Mobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive reviewMolecular Biology Reports, 2021
- Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella pneumoniaeBiomedicine & Pharmacotherapy, 2020
- The role of LpxA/C/D and pmrA/B g ene systems in colistin-resistant clinical strains of Acinetobacter baumanniiFrontiers in Laboratory Medicine, 2017
- Contribution of EmrAB efflux pumps to colistin resistance in Acinetobacter baumanniiJournal of Microbiology, 2017
- The outer membrane porin OmpW of Acinetobacter baumannii is involved in iron uptake and colistin bindingFEBS Letters, 2015
- Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant Acinetobacter baumanniiDiagnostic Microbiology and Infectious Disease, 2015